Page 112

173. Raine CS. 1997. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol.; 77: 135-52..

174. Raine CS, Cannella B, Hauser SL, Genain CP. 1999. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol.; 46: 144-60..

175. Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW. 1999. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev.; 30: 77-105..

176. Renno T, Taupin V, Bourbonniere L, et al. 1998. Interferon-gamma in progression to chronic demyelination and neurological deficit following acute EAE. Mol Cell Neurosci.; 12: 376-89..

177. Richards R, Burls A, Payne N. 2000. Cost utility of drugs for multiple sclerosis. Methods used don't calculate true benefit. BMJ.; 320: 1475.; discussion 1475-6.

178. Rieckmann P. 1997. Soluble adhesion molecules (sVCAM-1 and slCAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol.; 41: 236-333..

179. Rieckmann P, Albrecht M, Kitze B, et al. 1995. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol.; 37: 82-8..

180. Risch N. 1992. Genetic linkage: interpreting lod scores. Science.; 255: 803-4..

181. Ritchie JM. 1982. Sodium and potassium channels in regenerating and developing mammalian myelinated nerves. Proc R Soc Lond B Biol Sci.; 215: 273-87..

182. Rose NR. Immunologic Diagnosis of Autoimmunity. Leffell MS, Donnenber AD, Rose NRE. 1997. Handbook of Human Immology. Boca Raton. CRC Press. 111-124..

183. Rosen BR, Buckner RL, Dale AM. 1998. Event-related functional MRI: past, present, and future. Proc Natl Acad Sci U S A.; 95: 773-80..

184. Rosenblum D, Saffir M. 1998. The natural history of multiple sclerosis and its diagnosis. Phys Med Rehabil Clin N Am.; 9: 537-49..

185. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. 1996. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neur filament protein in CSF. J Neurochem.; 67: 2013-8..

186. Rovaris M, Viti B, Ciboddo G, Capra R, Filippi M. 2000. Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. J Neurol Sci.; 176: 128-30..

187. Rudick RA. 1999. Disease-modifying drugs for relapsing-remitting multiple sclerosis and f ture directions for multiple sclerosis therapeutics. Arch Neurol.; 56: 1079-84..

188. Sadovnick AD. 1993. Familial recurrence risks and inheritance of multiple sclerosis. Curr Opin Neurol Neurosurg.; 6: 189-94..

189. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. 1996. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet.; 347: 1728-30..

190. Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. 1996. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol.; 2: 249-58..

191. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. 1999. CD46 is a cellular receptor for human herpesvirus 6. Cell.; 99: 817-27..

192. Sater RA, Rostami AM, Galetta S, Farber RE, Bird SJ. 1999. Serial evoked potential studies and MRI imaging in chronic progressive multiple sclerosis. J Neurol Sci.; 171: 79-83..

193. Sawcer S, Goodfellow PN, Compston A. 1997. The genetic analysis of multiple sclerosis. Trends Genet.; 13: 234-9..

194. Schadlich HJ, Karbe H, Felgenhauer K. 1987. The prevalence of locally-synthesized virus antibodies in various forms of multiple sclerosis. J Neurol Sci.; 80: 343-9..

195. Schumacher GA, Beebe G, Kibler RF, Kurlant LT, Kurtzke JF, McDowell F. 1965. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Med.; 122: 552-568..